Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL TSE:HLS CVE:RX CVE:VM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.17-2.0%$1.30$0.77▼$2.63$96.62M1.04308,946 shs70,390 shsHLSHLS TherapeuticsC$4.91+0.4%C$4.87C$3.00▼C$5.23C$109.24M1.0713,541 shs35,800 shsRXBioSyentC$11.50+0.9%C$11.67C$9.20▼C$12.13C$131.53M0.934,171 shs1,577 shsVMVoyageur PharmaceuticalsC$0.19C$0.22C$0.04▼C$0.36C$28.79M0.32208,268 shs45,376 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-8.46%-13.14%-13.14%+17.82%-43.60%HLSHLS Therapeutics+0.41%+1.66%-1.21%+16.90%+42.32%RXBioSyent-0.09%-4.84%-1.89%+8.57%+14.00%VMVoyageur Pharmaceuticals0.00%-28.30%-15.56%+18.75%+245.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics2.4667 of 5 stars3.73.00.00.02.70.00.6HLSHLS TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARXBioSyentN/AN/AN/AN/AN/AN/AN/AN/AVMVoyageur PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.33Buy$8.00586.11% UpsideHLSHLS Therapeutics 2.00HoldC$4.50-8.35% DownsideRXBioSyent 0.00N/AN/AN/AVMVoyageur Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VM, CRDL, RX, and HLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AHLSHLS TherapeuticsC$40.13M2.72C$0.32 per share15.22C$2.51 per share1.95RXBioSyentC$34.06M3.86C$3.74 per share3.07C$3.22 per share3.57VMVoyageur PharmaceuticalsN/AN/AC$0.01 per share35.00C$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%8/11/2025 (Estimated)HLSHLS Therapeutics-C$15.53M-C$1.00N/A∞N/A-38.70%-25.27%-2.89%N/ARXBioSyentC$7.02MC$0.6218.66∞N/A20.60%20.01%12.86%N/AVMVoyageur Pharmaceuticals-C$1.66M-C$0.01N/A∞N/AN/A-117.77%-30.77%N/ALatest VM, CRDL, RX, and HLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CRDLCardiol Therapeutics-$0.11N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AHLSHLS TherapeuticsC$0.204.07%N/AN/A N/ARXBioSyentC$0.181.57%N/A29.21%N/AVMVoyageur PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.013.263.26HLSHLS Therapeutics86.501.561.01RXBioSyent2.903.926.91VMVoyageur Pharmaceuticals4.230.100.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%HLSHLS Therapeutics65.20%RXBioSyent1.37%VMVoyageur PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%HLSHLS Therapeutics0.37%RXBioSyent33.65%VMVoyageur Pharmaceuticals10.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.65 million78.31 millionNot OptionableHLSHLS Therapeutics9122.25 millionN/ANot OptionableRXBioSyentN/A11.44 millionN/ANot OptionableVMVoyageur PharmaceuticalsN/A151.52 millionN/ANot OptionableVM, CRDL, RX, and HLS HeadlinesRecent News About These CompaniesVoyageur Pharmaceuticals Ltd. (CVE:VM) Director Eugene Leonard Fritzel Acquires 32,250 SharesJuly 1, 2025 | insidertrades.comVoyageur Pharmaceuticals (CVE:VM) Trading 21.8% Higher - Here's WhyJune 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Shares Up 20% - Here's What HappenedJune 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Up 21.8% - Should You Buy?June 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Shares Up 23.6% - Time to Buy?June 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Up 20% - Should You Buy?June 27, 2025 | marketbeat.comVoyageur Pharmaceuticals (CVE:VM) Trading 12.7% Higher - Here's WhyJune 27, 2025 | marketbeat.comVoyageur Pharmaceuticals Launches First Commercial Sale of Barium Contrast AgentsJune 4, 2025 | msn.comVoyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study ResultsApril 24, 2025 | finance.yahoo.comVoyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market LaunchApril 1, 2025 | finance.yahoo.comVoyageur Pharmaceuticals Ltd.: Voyageur Clarifies Terms of Previously Announced AgreementMarch 3, 2025 | finanznachrichten.deVoyageur Advances MRI Drug Development Using Next Generation Endohedral FullerenesFebruary 18, 2025 | finance.yahoo.comVoyageur Pharmaceuticals With CEO, Brent Willis | February 6th, 2025February 6, 2025 | msn.comVoyageur Receives $600K Grant From Alberta Innovates for Product DevelopmentFebruary 6, 2025 | finance.yahoo.comVoyageur Secures $687k of Additional Capital From Warrant ExercisesJanuary 24, 2025 | finance.yahoo.comVoyageur Pharmaceuticals is going global: Why it's time to buy the stockJanuary 23, 2025 | msn.comCanadian Investment Regulatory Organization Trading Halt - VMDecember 21, 2024 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - VMDecember 21, 2024 | finance.yahoo.comOne of the best Venture pharma stocks has grown even strongerOctober 3, 2024 | msn.comVoyageur Pharmaceuticals Ltd (VM)August 10, 2024 | investing.comUpdate - Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium ContrastMay 28, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Infrastructure Stocks Riding the U.S. Building BoomBy Chris Markoch | July 14, 2025View 3 Infrastructure Stocks Riding the U.S. Building BoomBroadcom’s Big VMware Update: A Threat to Public Cloud Giants?By Leo Miller | June 28, 2025View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?VM, CRDL, RX, and HLS Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.17 -0.02 (-2.02%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.HLS Therapeutics TSE:HLSC$4.91 +0.02 (+0.41%) As of 07/17/2025 02:52 PM EasternHLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.BioSyent CVE:RXC$11.50 +0.10 (+0.88%) As of 09:34 AM EasternBioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.Voyageur Pharmaceuticals CVE:VMC$0.19 0.00 (0.00%) As of 09:31 AM EasternVoyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada, and the state of Utah. The company develops barium and iodine-based APIs. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. was founded in 2017 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
